Chairperson of the Board since January 2015 and Board member since December 2010. President and Chief Financial Officer of Ligmincha International, a 501(c)3 non-profit organization. Former Senior Managing Director and Chief Investment Officer for Third Security, LLC. Former Chief Investment Officer for Howe & Rusling. Former Chief Investment Officer and Board Member of the New River
Funds. Former Director of Market Research and Analysis at GIV Holding, Inc. Former member of the Boards of Directors’ of Intrexon Corporation, Cyntellect, Inc., Synchrony Inc., and the Virginia Biotechnology Association. Mr. Patzig holds a B.A. in Philosophy and an M.A. in Literature from Virginia Tech.
Mr. Riccitelli is currently an independent consultant. Most recently Mr. Riccitelli served as President and CEO and a director on the board of directors of Signal Genetics, a publicly traded molecular diagnostic company focused on serving the needs of patients suffering from Multiple Myeloma. Previously, Mr. Riccitelli has served as an independent consultant, as the PEVP and COO of Genoptix,
a publicly traded diagnostic services company focused on the needs of community hematologists and oncologists. Mr. Riccitelli has also held a number of R&D and general management leadership positions for Becton, Dickinson and Company, including most recently as a VP and GM and as a board member for BD Ventures. Mr. Riccitelli received a B.A. in Biology from Washington and Jefferson College and a M.S. Eng. degree from The University of Texas in Mechanical & Biomedical Engineering.
Ilan Danieli has served as Precipio's CEO since founding the company in early 2011. With over 20 years managing small and medium-size companies, some of his previous experiences include COO of Osiris, a publicly-traded company based in New York City with operations in the US, Canada, Europe and Capital Management, a multi-billion dollar hedge fund; and in various other entrepreneurial
ventures. Ilan holds an MBA from the Darden School at the University of Virginia, and a BA in Economics from Bar-Ilan University in Israel.
President and Chief Executive Officer of Bantam Pharmaceutical, LLC, since March 2016. Former Senior Vice President and General Manager, Discovery and Development Services, at Albany Molecular Research, Inc. and Corporate Vice President of Global Discovery Research Services at Charles River Laboratories. Former President and a member of the Board of
Directors of the David H. Murdock Research Institute, former Vice President and Site Head at Merck Frosst and various positions at GlaxoSmithKline. Bachelor of Science degree in Biology and Chemistry from North Carolina State University, a Master in Business Administration from Duke University, Fuqua School of Business, and a Ph.D. in Biophysical Chemistry from Saint Louis University School of Medicine.
Mark Rimer is a partner at Kuzari Group, a boutique private investment group with a broad mandate to invest in full or partial buy-outs, growth capital and venture capital across a broad range of industries. Mark serves on the Board of several companies, including Precipio, and is actively engaged with numerous portfolio companies. Prior to joining Kuzari, Mark
worked for a London-based private equity group - RP Capital Group, managing a number of investments in emerging markets. Mark is a Chartered Accountant, earned his undergraduate degree in Politics and Economics from Bristol University, and his MBA from the NY Stern School of Business.